← Leaderboards
Geoffrey Roger Hill
Fred Hutchinson Cancer Center
$15,826,079
Attributed
$16,685,113
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.5M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,339,944 · 8
By mechanism
P01$21,219,889 · 5
R01$7,876,300 · 2
U01$4,243,755 · 1
Top collaborators
- Motoko Koyama2 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Damian J. Green$13,222,447
- Meghan Anne Koch$2,049,282
- Motoko Koyama$1,311,574
- Joshua Aiden Hill$6,198,358
- Frederick R Appelbaum$23,398,619
Others in their field
Other Emerging Leaders on “Transplantation”
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$32,078,740
- Bronwen Shaw · Medical College Of Wisconsin$24,584,971
- Greg Westergaard · Alpha Genesis Inc$18,927,907
- Raghuveera Yaramolu · Eminent Services Corporation$9,791,923
- Kirsten Johansen · Hennepin Healthcare Research Institute$9,776,955
- William H. Peranteau · Children'S Hosp Of Philadelphia$7,624,302
Research focus
TransplantationT-LymphocyteImmunityPreventGraft Vs Host DiseasePre-ClinicalGraft Vs Leukemia EffectMediatingInflammationPathway InteractionsNatural Killer CellsInnovationPreclinical StudyPreventionCurative TreatmentsPost-TransplantMortalityMalignant NeoplasmsCyclophosphamideCytokineResponseT Cell ResponseFlow CytometryAllogenic
Grant awards (30)
Adult Leukemia Research Center$4,395,431
P01 · FY2025 · CA · contact PI
Preventing GVHD by inhibition of alloantigen presentation in the gut$878,801
R01 · FY2025 · HL · contact PI
Defining the Mechanisms of Immune Escape After Adoptive T cell Therapies$845,088
P01 · FY2025 · CA · contact PI
Defining Protective CMV Immunity after Transplantation$750,866
R01 · FY2025 · AI · contact PI
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow$456,745
P01 · FY2025 · CA · contact PI
Core A: Administration$193,172
P01 · FY2025 · CA · contact PI
Adult Leukemia Research Center$4,359,202
P01 · FY2024 · CA · contact PI
Defining the Mechanisms of Immune Escape After Adoptive T cell Therapies$846,699
P01 · FY2024 · CA · contact PI
Preventing GVHD by inhibition of alloantigen presentation in the gut$839,267
R01 · FY2024 · HL · contact PI
Defining Protective CMV Immunity after Transplantation$735,894
R01 · FY2024 · AI · contact PI
Core A: Administration$155,332
P01 · FY2024 · CA · contact PI
Preventing GVHD by inhibition of alloantigen presentation in the gut$856,395
R01 · FY2023 · HL · contact PI
Defining Protective CMV Immunity after Transplantation$757,310
R01 · FY2023 · AI · contact PI
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow$510,637
P01 · FY2023 · CA · contact PI
Adult Leukemia Research Center$3,910,199
P01 · FY2022 · CA · contact PI
Preventing GVHD by inhibition of alloantigen presentation in the gut$777,776
R01 · FY2022 · HL · contact PI
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow$557,823
P01 · FY2022 · CA · contact PI
Optimizing myeloma-specific immunity after autologous stem cell transplantation$84,415
U01 · FY2022 · CA · contact PI
Adult Leukemia Research Center$2,292,615
P01 · FY2021 · CA · contact PI
Adult Leukemia Research Center$1,697,384
P01 · FY2021 · CA · contact PI
Preventing GVHD by inhibition of alloantigen presentation in the gut$562,863
R01 · FY2021 · HL · contact PI
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow$380,582
P01 · FY2021 · CA · contact PI
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow$241,565
P01 · FY2021 · CA · contact PI
Preventing GVHD by inhibition of alloantigen presentation in the gut$190,801
R01 · FY2021 · HL · contact PI
Preventing Myeloma Relapse after Autologous Stem Cell Transplantation with Decoy Resistant IL-18$165,584
U01 · FY2021 · CA · contact PI
Preventing GVHD by inhibition of alloantigen presentation in the gut$759,622
R01 · FY2020 · HL · contact PI
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow$377,415
P01 · FY2020 · CA · contact PI
Optimizing myeloma-specific immunity after autologous stem cell transplantation$2,208,097
U01 · FY2019 · CA · contact PI
Optimizing myeloma-specific immunity after autologous stem cell transplantation$1,785,659
U01 · FY2019 · CA · contact PI
Preventing GVHD by inhibition of alloantigen presentation in the gut$766,705
R01 · FY2019 · HL · contact PI